Puc H S, Bajorin D F, Bosl G J, Amsterdam A, Motzer R J
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Invest New Drugs. 1995;13(2):163-5. doi: 10.1007/BF00872866.
Fifteen patients with advanced, cisplatin-refractory germ cell tumors (GCT) were treated on a phase II trial with topotecan. None of the 14 evaluable patients achieved a complete or partial response. Myelosuppression was the major toxicity. The median nadir leukocyte count was 1.75 cells/mm3, neutrophil count was 1.55 cells/mm3, hemoglobin was 8.75 gm/dl, and platelet count was 20,500 cells/mm3. Topotecan is not efficacious in the treatment of cisplatin-refractory GCT.
15例晚期顺铂难治性生殖细胞肿瘤（GCT）患者接受了拓扑替康的II期试验治疗。14例可评估患者中无一例获得完全或部分缓解。骨髓抑制是主要毒性。白细胞计数最低点的中位数为1.75细胞/mm³，中性粒细胞计数为1.55细胞/mm³，血红蛋白为8.75 g/dl，血小板计数为20,500细胞/mm³。拓扑替康对顺铂难治性GCT治疗无效。
